论文部分内容阅读
丙型肝炎(hepatitis c virus,HCV)是由于感染了HCV病毒引起的一种病毒性肝炎,主要通过血液、医疗器械和吸毒传播。HCV病毒感染初期可引起肝脏慢性炎症坏死和纤维化,进一步发展成为肝硬化、肝癌等终末期肝病。HCV治疗的目的就是清除患者体内病毒,控制或减轻肝组织纤维化或炎症坏死现象,避免其发展成肝硬化,从而降低原发性肝癌发生几率。目前常规的治疗方案是利巴韦林联合长效干扰素治疗,但是该方法仅有大概一半的患者能产生持续的病毒学应答。本文就近年来HCV治疗的研究进展做一综述。
Hepatitis C virus (HCV) is a type of viral hepatitis caused by the infection of the HCV virus, mainly through blood, medical devices and drug use. The initial stage of HCV infection can cause chronic inflammation, necrosis and fibrosis in the liver and further develop into end-stage liver disease such as liver cirrhosis and liver cancer. The purpose of HCV treatment is to remove the virus in patients with the body, control or reduce liver fibrosis or inflammation and necrosis, to avoid the development of cirrhosis, thereby reducing the incidence of primary liver cancer. The current regimen is ribavirin combined with long-acting interferon therapy, but only about half of patients in this method produce a sustained virological response. This article reviews the progress of HCV therapy in recent years.